To test the hypothesis that prostacyclin (PGI2) is formed via a biochemical interaction between platelets and lymphocytes, we measured eicosanoids by high performance liquid chromatography (HPLC) and radioimmunoassay (RIA). A distinct 6-keto-prostaglandin Fl, (6KPGF1,,) peak was noted when [14Clarachidonic acid ([14CjAA) was added to the mixed cell preparations which was increased by pretreating platelets with 1-benzylimidazole (1-BI). Lymphocytes prelabeled with [14CIAA failed to form 6KPGF1, when stimulated with phytohemagglutinin (PHA) or ionophore A23187. When the prelabeled platelets were suspended together with aspirin-treated lymphocytes and stimulated with ionophore, thrombin, or collagen, a 6KPGF1, peak was detected and enhanced by 1-BI. These results were supported by quantifying the 6KPGF1, content in the HPLCpurified fraction by RIA. Adding prostaglandin H2 (PGH2) directly to lymphocytes led to 6KPGF1,, production. Platelet aggregation and release were inhibited by lymphocytes in a doserelated manner. We conclude that lymphocytes possess PG12 synthase activity which is capable of converting platelet-derived PGH2 into PGI2. PGI2 formed is sufficient to inhibit platelet function.
Introduction
Human lymphocytes are capable of taking up arachidonic acid (AA)' and incorporating it into their phospholipids, yet they appear to possess minimal ability to convert that arachidonate into biologically active metabolites (1, 2 Receivedfor publication 5 May 1986 and in revisedform 13 January 1987. 1 . Abbreviations used in this paper: AA, arachidonic acid; 1-BI, 1-benzylimidazole; HETE, hydroxyeicosatetraenoic acid; HHT, 12-hydroxyheptadecatrienoic acid; 6KPGF1,,, 6-keto-prostaglandin Fl,,; PHA, phytohemagglutinin; PPP, platelet-poor plasma; PRP, platelet-rich plasma; PG, prostaglandin; PGI2, prostacyclin; TX, thromboxane. and 12-HETE upon treating lymphocytes with phytohemagglutinin (PHA) (1) . These metabolites were thought to be due to contamination ofthe lymphocyte preparation with platelets and neutrophils. Goldyne (2) . Hence, lymphocytes probably contain little or no cyclooxygenase activity to metabolize AA into active products such as TXA2 or prostacyclin (PGI2).
Recent data have shown that the serum content of 6-ketoprostaglandin Fl (6KPGFI,) is significantly higher than that of plasma (3, 4) . This difference must be due to PGI2 synthesis by blood cells stimulated during the coagulation process. However, the identity of the cells responsible for PGI2 synthesis remains unknown. Since none ofthe isolated blood cell fractions produces PGI2 directly, one must consider the possibility that PGI2 is synthesized via a biochemical interaction between two different classes of cells. The purpose of this study was to test the hypothesis that, despite their lack of cyclooxygenase activity, blood lymphocytes possess PGI2 synthase activity which can convert platelet-derived (PG) endoperoxides into PGI2. PGH2 purification. PGH2 was prepared using AA and ram seminal vesicle microsomes, and the biosynthetically produced PGH2 was purified over a gravity flow silicic acid column and a cyanobonded phase HPLC self-packed column using a hexane-isopropanol gradient (5) . The purified product is free from other eicosanoids as analyzed by gas chromatography-mass spectrometry. This ultrapurified PGH2 was active in inducing human platelet aggregation in low micromolar concentrations.
Preparation of lymphocytes and platelets. Both lymphocytes and platelets were isolated from venous blood of healthy human subjects. Lymphocyte suspensions were prepared by the Ficoll-Hypaque separation technique (6) . Platelet and monocyte contaminations in the lymphocyte preparations were evaluated by light microscopic and scanning electron microscopic examinations. Scanning electron microscope work was performed by Dr. Bucana at University ofTexas Cancer Center, Department of Cell Biology. The lymphocyte preparations were contaminated by a small percentage of platelets ranging from 3 to 15%. Monocyte contamination was not detected by either microscopic examination. In some experiments, lymphocytes were inactivated by boiling at 100'C for 3 min. There was no apparent cell agglutination in the boiled lymphocyte preparation. Washed platelet suspensions were prepared according to the method described by Walsh (7) . The final preparation was suspended in Tyrode's buffer containing 5 mM calcium and 0.5 mg/ml human fibrinogen. Only freshly prepared cell suspensions were used. To obtain washed buffy coat preparations, venous blood was drawn into tubes containing 1/10 vol of 3.8% sodium citrate, mixed and centrifuged at 3,000 g for 20 min. After removing plasma, the buffy-coat layer was carefully separated and washed three times in Tyrode's buffer and the final preparation was suspended in 2 ml Tyrode's buffer that contained 5 (8). Recovery for eicosanoids was -95%. The eicosanoids were analyzed by reverse phase HPLC (model Vista 5500 HPLC; Varian Associates, Inc., Palo Alto, CA). The prostanoids were separated using an isocratic solvent system of 35% acetonitrile in acidified water. After initial isocratic period, the solvent composition was changed to 50% acetonitrile in acidified water and ran for 10 min to elute HHT, leukotriene B4, and HETEs. Next, a slight convex gradient was run from 50 to 75% acetonitrile for 8 min and then to 100% acetonitrile. Fractions were collected and the radioactivity was counted in a #-scintillation counter. Tritiated standards were used to determine the relative retention time of each eicosanoid.
RIA. Eicosanoids were separated by HPLC as described above and the fractions corresponding to 6KPGFI,, were pooled and assayed for 6KPGFI. by a highly sensitive and specific RIA (9) . To ascertain that an optimal amount of 12-HETE was produced at 3 min after addition of an agonist, we measured 12-HETE produced by platelet stimulated with 10 jM AA at 1, 3, 5, and 30 min by RIA (Seragen, Milford, MA). Our data indicated that the production reached plateau at 3 min. 12-HETE at these time points was 663, 852, 700, and 878 ng/ml, respectively. Platelet aggregation. Platelet aggregation was measured by the turbidimetric method of Born (10) using a dual-channel aggregometer (Chrono-Log Corp., Havertown, PA). The procedure was modified to provide an appropriate control for reduced light transmission caused by the addition of lymphocyte preparation. For example, to determine the effect of lymphocytes on platelet aggregation, the platelet-rich plasma (PRP) cuvette in the aggregometer contained 0.2 ml oflymphocyte preparations (varying concentrations) and 0.8 ml of washed platelet suspensions (3 X 108/ml), whereas the platelet-poor plasma (PPP) cuvette contained 0.2 ml of lymphocyte preparation at an identical concentration and 0.8 ml ofthe Tyrode's buffer used to suspend washed platelets. The mixtures were incubated at 370C under constant stirring for 1 min before addition of the agonists: collagen (2-15 ,ug/ml), thrombin (0.05-0.1 U/ ml), AA (10-20 MM), or buffer control. The extent of change in light transmission was continuously recorded for 5 min. In all of the experiments performed using this modified procedure, the addition of lymphocytes to platelet suspensions without agonists caused minimal changes in light transmission. For the regular platelet aggregation experiments in which lymphocytes were not added, buffer alone was placed in the PPP cuvette. The concentration of each agonist was determined experimentally as the minimal concentration inducing maximal aggregation.
The PGI2-like activity was assayed by relating the percent inhibition of platelet aggregation of a tested sample to a calibration curve constructed by using varying concentrations of authentic PGI2 as previously described (1 1).
Platelet serotonin release. Platelet serotonin release was performed according to the method of Weiss et al. (12) with minor modification.
In brief, 3 X 108 platelets/ml PRP was labeled with 2 AM ['4C]serotonin at room temperature for 30 min and 20 jIM imipramine was then added.
0.45 ml of labeled PRP was incubated with 0.05 ml of lymphocytes or buffer in an aggregometer cuvette at 370C for 6 min under constant stirring. The stirring bar was removed and the sample was centrifuged at 13,000 g for 1 min in an Eppendorf microfuge (Brinkmann Instruments, Inc., Westbury, NY). The radioactivity was determined in a I8-scintillation counter.
Results Fig. 1 (Table I) . When the prelabeled platelets were suspended together with aspirin-treated lymphocyte preparations and stimulated with ionophore, thrombin, and collagen, 6KPGFIa peak was detected and was enhanced by treating platelets with 1-BI (Table I) . PGE2, PGF2., and PGD2 peiks were also increased by treating the cells with the TX synthase inhibitor. The 12-HETE peak was discernible in all the cell preparations, including ionophore-treated lymphocytes prelabeled with ['4C]AA. The eicosanoid profile ofionophore-treated lymphocytes was similar to that ofionophore-treated platelets, which was consistent with the view that the eicosanoids released in the stimulated lymphocyte preparation were contributed primarily by the contaminating platelets.
In separate experiments, HPLC fractions corresponding to the 6KPGFia peak were collected and the 6KPGFIa content was measured by RIA. Results are shown in Fig. 2 . Lymphocyte preparations (I07 cells/ml) produced 0.18 ng of 6KPOFIa (mean ofthree experiments) when incubated with 10 ,uM AA for 3 min at 37°C (Fig. 2 A) . Lymphocytes incubated with platelets in the absence ofexogenous AA did not produce measurable quantities of 6KPGFIa, yet in the presence of 10 gM AA, lymphocyte and platelet mixtures produced an average of 1.39 ng of 6KPGFI,.
(almost an eightfold increase over lymphocytes alone) (Fig. 2  B) . 6KPGFia production was further enhanced by pretreating platelets with 5 mM 1-BI (Fig. 2 C) . These results suggest that lymphocytes do not metabolize AA directly, but that they possess sufficient PGI2 synthase activity to synthesize PG12 from PGH2. To test this hypothesis, 5 ,uM ultrapurified PGH2 was incubated with washed lymphocytes. The supernatant was applied to HPLC, and 6KPGFIa content in the HPLC fractions was measured by RIA. Significant quantities of 6KPGFI. were synthesized (Fig. 2 D) . PGH2 incubated in buffer alone under similar (Fig. 3) . The degree of inhibition was related to the lymphocyte concentrations added to the platelet suspensions (Fig. 4) . To determine whether the inhibiting effect of lymphocytes was primarily due to PGI2 generation, we measured the 6KPGF1,, content in the aggregometer supernatant by bioassay and RIA. Platelets (3 X 108/ml) and lymphocytes (1 X 107/ml) were co-incubated by 370C in an aggregometer cuvette for 1 min followed by addition of 10 ug/ml collagen. Platelet aggregation was continuously recorded. At the end of 5 min, the cuvette was removed from the aggregometer, the stirring bar was removed, and the sample was rapidly spun at 13,000 g to remove the cells. The 6KPGF1a content in the supernatant was determined by RIA. The antiaggregatory activity ofPGI2 in the sample was determined by relating the percent inhibition of platelet aggregation to a calibration curve established in each experiment. The mean PGI2 antiaggregating activity from three experiments was 1.56 ng/ml, whereas the 6KPGFIa content measured by RIA was 1.48 ng/ml, hence, similar values were obtained by two very different assay methods.
Discussion
Our data support the hypothesis that PGI2 is produced through the interaction of blood platelets and lymphocytes. Three sep- gas chromatography-mass spectrometry (13) . The second line of evidence is afforded by the close approximation of the 6KPGF1, values obtained by the HPLC-RIA and the bioassay.
The notion that lymphocyte PGI2 production depends on platelet-generated PGH2 is consistent with several of our observations. For instance, PGI2 production by the platelet-lymphocyte mixture requires the initial activation of platelets. Pretreatment ofplatelets with a cyclooxygenase inhibitor abolishes lym- phocyte PGI2 production, whereas blocking platelet TX synthase activity with a specific inhibitor enhances it. PGI2 is formed when aspirin-treated lymphocytes are incubated with radiolabeled platelets and then stimulated with calcium ionophore, thrombin, or collagen, whereas lymphocytes alone fail to produce PGI2 despite stimulation with PHA and ionophore. Direct evidence was provided in this study by demonstrating a significant production of 6KPGFia by washed lymphocytes treated with a highly purified PGH2 preparation. Availability ofthis pure PGH2 preparation permits us to document unequivocally that lymphocytes possess sufficient PGI2 synthase enzyme to metabolize PGH2 into biologically active PGI2-We have compared the major metabolites in lymphocyte, platelet, and lymphocyte-platelet preparations stimulated with the calcium ionophore. Except for the presence of 6KPGF1,, which is formed in the platelet-lymphocyte mixture only, major metabolites generated in these three cell preparations are similar. These data, particularly the approximation of 12-HETE production in all three preparations, indicate that these metabolites are generated by platelets. Measurement of 12-HETE is useful for assessing monocyte contamination because blood monocytes do not synthesize 12-HETE. A significant monocyte contamination should lower the 12-HETE content in the lymphocyte preparation. Based on the eicosanoid profile and our microscopic data, we conclude that the eicosanoids generated by lymphocyte preparation are derived from platelet and not from monocyte contaminants. The contaminated platelet concentration (106/ ml), however, is too low to provide lymphocytes with sufficient PGH2 to synthesize a detectable quantity ofPGI2. The eicosanoid data shown in Table I also indicate that both calcium ionophore and thrombin produce a similar eicosanoid profile when added to the lymphocyte-platelet mixture, whereas collagen is a weaker stimulator of AA metabolism. Blocking of platelet TX synthase in all these preparations leads to formation of a discernible quantity of PGD2 and PGE2. These compounds may further enhance the antiplatelet aggregating effect of PGI2 produced in the same mixture.
Treatment of platelets with physiologic agonists in the presence of lymphocytes triggers the production of sufficient PGI2 to inhibit platelet aggregation. Changes in platelet aggregation tracings are not merely due to the masses oflymphocytes, which may impede the light transmission, because (a) the inhibiting effect was evident when a separate platelet function marker (i.e., ['4C]serotonin release) was used, (b) the inhibiting effect was related to the concentration ofthe agonist added without changing lymphocyte and platelet concentrations and therefore should not be due to an artificial effect of lymphocyte masses, (c) the antiplatelet effect correlated well with the quantity of PGI2 produced as measured by both the bioassay and the RIA, and (d) each experiment had a carefully standardized internal blank control. Inhibition of platelet function depends on the lymphocyte concentration. In fact, even 106 lymphocytes per millimeter ofplatelet preparation that contained 3 X 108 platelets exhibited appreciable platelet inhibition.
Our observations resolve the mystery ofwhy serum 6KPGF1a levels are higher than the plasma levels. Both the buffy-coat cells and the platelet-lymphocyte mixture experiments indicate that during blood coagulation, generation ofthrombin leads to platelet activation and initiation of AA metabolism. Platelet-derived PGH2 is released and utilized by lymphocytes to form PGI2. It is unclear whether this process requires direct cell-to-cell contact. Nevertheless, it may represent an important mechanism whereby PGI2 can be effectively produced without relying on a single cell source. Platelets appear to function as a donor of PGH2 for several other cells to synthesize PGI2. For example, we have recently shown that PGI2 is produced by subendothelial smooth muscle cells through platelet donation of PGH2 (14) . Platelets are also donors of PGH2 for cultured endothelial cells to synthesize PGI2 (15) (16) (17) . Although the individual quantity of PGI2 produced by each cell-cell interaction is small, summation of the total PGI2 produced will have a powerful biological activity. This may represent a major mechanism whereby PGI2 acts as an effective autocoid in modulating hemostasis, inflammation, and immune responses.
